[go: up one dir, main page]

MX2019006169A - Derivados sililados de resveratrol y su uso en enfermedades neurodegenerativas, neurologicas o inflamatorias. - Google Patents

Derivados sililados de resveratrol y su uso en enfermedades neurodegenerativas, neurologicas o inflamatorias.

Info

Publication number
MX2019006169A
MX2019006169A MX2019006169A MX2019006169A MX2019006169A MX 2019006169 A MX2019006169 A MX 2019006169A MX 2019006169 A MX2019006169 A MX 2019006169A MX 2019006169 A MX2019006169 A MX 2019006169A MX 2019006169 A MX2019006169 A MX 2019006169A
Authority
MX
Mexico
Prior art keywords
reservatrol
neurological
neurodegenerative
inflammatory diseases
silylated derivatives
Prior art date
Application number
MX2019006169A
Other languages
English (en)
Inventor
Carlos MORALES SÁNCHEZ Juan
Peñalver Puente Pablo
BELMONTE RECHE Efres
GONZÁLEZ REY Elena
Luisa Mateos Martín María
Original Assignee
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion
Publication of MX2019006169A publication Critical patent/MX2019006169A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
    • C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un grupo de compuestos derivados del resveratrol que presentan como sustituyentes al menos un grupo sililo que a su vez puede estar sustituido por distintos grupos. La invención también se refiere al uso terapéutico de estos compuestos en enfermedades inflamatorias, neurológicas y neurodegenerativas.
MX2019006169A 2016-11-30 2017-11-23 Derivados sililados de resveratrol y su uso en enfermedades neurodegenerativas, neurologicas o inflamatorias. MX2019006169A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201631535A ES2674744B1 (es) 2016-11-30 2016-11-30 Derivados sililados de resveratrol y su uso en enfermedades neurodegenerativas, neurologicas o inflamatorias
PCT/ES2017/070776 WO2018100219A1 (es) 2016-11-30 2017-11-23 Derivados sililados de resveratrol y su uso en enfermedades neurodegenerativas, neurológicas o inflamatorias

Publications (1)

Publication Number Publication Date
MX2019006169A true MX2019006169A (es) 2019-07-10

Family

ID=62241257

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006169A MX2019006169A (es) 2016-11-30 2017-11-23 Derivados sililados de resveratrol y su uso en enfermedades neurodegenerativas, neurologicas o inflamatorias.

Country Status (9)

Country Link
US (1) US11365208B2 (es)
EP (1) EP3549929A4 (es)
JP (1) JP7082977B2 (es)
CN (1) CN109996777A (es)
AU (1) AU2017368843B2 (es)
CA (1) CA3044908A1 (es)
ES (1) ES2674744B1 (es)
MX (1) MX2019006169A (es)
WO (1) WO2018100219A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112110966B (zh) * 2020-10-14 2023-10-03 牛倩 白藜芦醇糖苷类衍生物、制备和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7705188B2 (en) * 2002-04-10 2010-04-27 Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University Structural modification of resveratrol: sodium resverastatin phosphate
WO2003094833A2 (en) * 2002-05-10 2003-11-20 Orchid Chemicals & Pharmaceuticals Limited A new stereoselective route to produce tris-o-substituted-(e)-( 3,5-dihydroxyphenyl)-2-(4- hydroxyphenyl)ethene
ES2362065B1 (es) * 2009-12-15 2012-05-18 Consejo Superior De Investigaciones Cient�?Ficas (Csic) Compuestos con actividad antiinflamatoria.
KR101206123B1 (ko) * 2010-11-25 2012-11-28 영남대학교 산학협력단 스틸벤 골격을 갖는 화합물의 합성방법
CN102675100A (zh) 2011-10-31 2012-09-19 牛婧 白藜芦醇的酯衍生物和医疗用途
CN103709050A (zh) 2012-09-28 2014-04-09 中山大学 白藜芦醇衍生物及其在制备抗阿尔茨海默病药物中的应用
JP6262569B2 (ja) * 2014-03-03 2018-01-17 国立大学法人宇都宮大学 レスベラトロール誘導体及びチロシナーゼ活性阻害剤
CN103922981B (zh) * 2014-04-21 2017-01-04 苏州大学 一种化合物及其应用
EP3134421B1 (en) * 2014-04-24 2022-04-20 Institut National de la Santé et de la Recherche Médicale (INSERM) New lipophenol compounds and uses thereof

Also Published As

Publication number Publication date
AU2017368843A1 (en) 2019-06-06
JP7082977B2 (ja) 2022-06-09
AU2017368843B2 (en) 2021-12-16
EP3549929A4 (en) 2020-07-08
JP2020514249A (ja) 2020-05-21
ES2674744B1 (es) 2019-04-08
US11365208B2 (en) 2022-06-21
ES2674744A1 (es) 2018-07-03
WO2018100219A1 (es) 2018-06-07
US20190284213A1 (en) 2019-09-19
CA3044908A1 (en) 2018-06-07
CN109996777A (zh) 2019-07-09
EP3549929A1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
WO2016011306A3 (en) Terminal modifications of polynucleotides
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12016501702B1 (en) Pyrazole amide derivative
EA201990400A1 (ru) Соединения и композиции и их применение
WO2014152965A3 (en) Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
GEP20196961B (en) 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139
GB2533454A (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EA034135B9 (ru) Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов
MX382175B (es) Composiciones de profármaco de monometilfumarato
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MY184366A (en) Pyrazines modulators of gpr6
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
MX2019006169A (es) Derivados sililados de resveratrol y su uso en enfermedades neurodegenerativas, neurologicas o inflamatorias.